Search Results
T-Cell Engagers: targets, challenges and opportunity
The challenge of targeting solid tumors with T cells I TIL therapies I TCR Ts
Innovations from the therapeutics antibody space: obligate bispecific antibodies & T cell engagers
What are the differences between CAR T-cell therapy and bispecific antibodies?
BI 764532: a novel T-cell engager for patients with DLL3+ SCLC and NEC
2024 WMIF| The Reemergence of ADCs, Precision Medicine, T-Cell Engagers, & Bispecifics
T Cell Engager Antibodies – focus on Hematological Malignancies | Presented by Dr. John Kuruvilla
The value of bispecific T-cell engager therapies in myeloma & future considerations for these agents
Bispecific T-cell engagers in the treatment of myeloma
Targeting T Cells Within the Cancer Immunity Cycle
2024 WMIF | The Innovation Gap: Understanding the Role of Cell Therapies in Autoimmune Disease
CAR-T in solid tumors: challenges and future directions
